BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35512029)

  • 1. Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy.
    Xu Y; Yu Z; Fu H; Guo Y; Hu P; Shi J
    ACS Appl Mater Interfaces; 2022 May; 14(19):21836-21847. PubMed ID: 35512029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
    Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
    Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.
    Zeng L; Li J; Wang Y; Qian C; Chen Y; Zhang Q; Wu W; Lin Z; Liang J; Shuai X; Huang K
    Nanomedicine; 2014 Feb; 10(2):463-72. PubMed ID: 24028894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous inhibition of PFKFB3 and GLS1 selectively kills KRAS-transformed pancreatic cells.
    Ozcan SC; Mutlu A; Altunok TH; Gurpinar Y; Sarioglu A; Guler S; Muchut RJ; Iglesias AA; Celikler S; Campbell PM; Yalcin A
    Biochem Biophys Res Commun; 2021 Sep; 571():118-124. PubMed ID: 34325126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutaminase 1 plays a key role in the cell growth of fibroblast-like synoviocytes in rheumatoid arthritis.
    Takahashi S; Saegusa J; Sendo S; Okano T; Akashi K; Irino Y; Morinobu A
    Arthritis Res Ther; 2017 Apr; 19(1):76. PubMed ID: 28399896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
    Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
    Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
    Mehta A; Dalle Vedove E; Isert L; Merkel OM
    Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant KRAS is a druggable target for pancreatic cancer.
    Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer.
    Pan T; Gao L; Wu G; Shen G; Xie S; Wen H; Yang J; Zhou Y; Tu Z; Qian W
    Biochem Biophys Res Commun; 2015 Jan; 456(1):452-8. PubMed ID: 25482439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. siRNA-Loaded Hydroxyapatite Nanoparticles for
    Luo D; Xu X; Iqbal MZ; Zhao Q; Zhao R; Farheen J; Zhang Q; Zhang P; Kong X
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer.
    Elgogary A; Xu Q; Poore B; Alt J; Zimmermann SC; Zhao L; Fu J; Chen B; Xia S; Liu Y; Neisser M; Nguyen C; Lee R; Park JK; Reyes J; Hartung T; Rojas C; Rais R; Tsukamoto T; Semenza GL; Hanes J; Slusher BS; Le A
    Proc Natl Acad Sci U S A; 2016 Sep; 113(36):E5328-36. PubMed ID: 27559084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
    Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
    Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth.
    Raho S; Capobianco L; Malivindi R; Vozza A; Piazzolla C; De Leonardis F; Gorgoglione R; Scarcia P; Pezzuto F; Agrimi G; Barile SN; Pisano I; Reshkin SJ; Greco MR; Cardone RA; Rago V; Li Y; Marobbio CMT; Sommergruber W; Riley CL; Lasorsa FM; Mills E; Vegliante MC; De Benedetto GE; Fratantonio D; Palmieri L; Dolce V; Fiermonte G
    Nat Metab; 2020 Dec; 2(12):1373-1381. PubMed ID: 33230296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS: feeding pancreatic cancer proliferation.
    Bryant KL; Mancias JD; Kimmelman AC; Der CJ
    Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
    Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
    Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer.
    Udupa S; Nguyen S; Hoang G; Nguyen T; Quinones A; Pham K; Asaka R; Nguyen K; Zhang C; Elgogary A; Jung JG; Xu Q; Fu J; Thomas AG; Tsukamoto T; Hanes J; Slusher BS; Cooper AJL; Le A
    Proteomics; 2019 Nov; 19(21-22):e1800451. PubMed ID: 31231915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Milk exosomes - Natural nanoparticles for siRNA delivery.
    Aqil F; Munagala R; Jeyabalan J; Agrawal AK; Kyakulaga AH; Wilcher SA; Gupta RC
    Cancer Lett; 2019 May; 449():186-195. PubMed ID: 30771430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
    Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
    Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral cancer cells may rewire alternative metabolic pathways to survive from siRNA silencing of metabolic enzymes.
    Zhang M; Chai YD; Brumbaugh J; Liu X; Rabii R; Feng S; Misuno K; Messadi D; Hu S
    BMC Cancer; 2014 Mar; 14():223. PubMed ID: 24666435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting GLS1 to cancer therapy through glutamine metabolism.
    Yu W; Yang X; Zhang Q; Sun L; Yuan S; Xin Y
    Clin Transl Oncol; 2021 Nov; 23(11):2253-2268. PubMed ID: 34023970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.